Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H17N5O6S2 |
Molecular Weight | 427.455 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\C3=CSC(N)=N3)C2=O)C(O)=O
InChI
InChIKey=WYUSVOMTXWRGEK-HBWVYFAYSA-N
InChI=1S/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1
Cefpodoxime is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Cefpodoxime is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions: acute otitis media; pharyngitis and/or tonsillitis; community-acquired pneumonia; acute bacterial exacerbation of chronic bronchitis; gonorrhea; uncomplicated skin and skin structure infections; acute maxillary sinusitis and uncomplicated urinary tract infections (cystitis). Common adverse reactions include diarrhea, nausea, vaginal fungal infections, vulvovaginal infections, abdominal pain, headache. Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
81.7 µM [IC50] | |||
133.0 µM [IC50] | |||
133.0 µM [IC50] | |||
133.0 µM [IC50] |
Conditions
PubMed
Title | Date | PubMed |
---|---|---|
In vitro transfer of methicillin resistance determinants mecA from methicillin resistant Staphylococcus aureus (MRSA) to methicillin susceptible Staphylococcus aureus (MSSA). | 2017 Apr 4 |
|
Characterization of ESBL-producing Escherichia coli recovered from companion dogs in Tai'an, China. | 2017 Mar 31 |
Sample Use Guides
The recommended dosages, durations of treatment, and applicable patient population are: Pharyngitis and/or tonsillitis 100 mg Q 12 hours (5 to 10 days) Acute community-acquired pneumonia 200 mg Q 12 hours (14 days) Acute bacterial exacerbations of chronic bronchitis 200 mg Q 12 hours (10 day) Uncomplicated gonorrhea (men and women) and rectal gonococcal infections (women) 200 mg single dose Skin and skin structure 400 mg Q 12 hours (7 to 14 days) Acute maxillary sinusitis 200 mg Q 12 hours (10 days) Uncomplicated urinary tract infection 100 mg Q 12 hours (7 days).
Route of Administration:
Oral
The in-vitro activity of cefpodoxime was studied in 529 clinical isolates and compared with the activity of other oral beta-lactams. Amongst the Enterobacteriaceae cefpodoxime was very active (MIC90 less than or equal to 1 mg/l--other than genera commonly possessing chromosomal beta-lactamases). Against these strains cefpodoxime was comparable in activity to cefixime and about eight-fold more active than cefuroxime and 8-16-fold more active than cefaclor and cephalexin. Staphylococcus aureus strains were moderately susceptible (MIC90 4 mg/l) to cefpodoxime.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
WHO-ATC |
J01DD13
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000175488
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
WHO-VATC |
QJ01DD13
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
LIVERTOX |
168
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
CFR |
21 CFR 520.370
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
WHO-ATC |
J01DD64
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
80210-62-4
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | |||
|
CEFPODOXIME
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | |||
|
20489
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | RxNorm | ||
|
CHEMBL1201016
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | |||
|
6335986
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | |||
|
SUB07414MIG
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | |||
|
6123
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | |||
|
C65305
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | |||
|
C053268
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | |||
|
80210-62-4
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | |||
|
M3212
Created by
admin on Mon Oct 21 19:50:25 UTC 2019 , Edited by admin on Mon Oct 21 19:50:25 UTC 2019
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)